Currently, there are 50.14M common shares owned by the public and among those 44.59M shares have been available to trade.
The company’s stock has a 5-day price change of 73.94% and 111.61% over the past three months. GLUE shares are trading 67.79% year to date (YTD), with the 12-month market performance up to 279.20% higher. It has a 12-month low price of $2.44 and touched a high of $8.84 over the same period. GLUE has an average intraday trading volume of 347.15K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 77.28%, 65.94%, and 78.42% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) shares accounts for 62.08% of the company’s 50.14M shares outstanding.
It has a market capitalization of $581.79M and a beta (3y monthly) value of 1.42. The earnings-per-share (ttm) stands at -$2.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 25.53% over the week and 11.05% over the month.
Analysts forecast that Monte Rosa Therapeutics Inc (GLUE) will achieve an EPS of -0.49 for the current quarter, -0.49 for the next quarter and -1.87 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.59 while analysts give the company a high EPS estimate of -0.59. Comparatively, EPS for the current quarter was -0.7 a year ago. Earnings per share for the fiscal year are expected to increase by 28.94%, and 4.60% over the next financial year.
Looking at the support for the GLUE, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on February 15, 2024, with the firm’s price target at $11. Wells Fargo coverage for the Monte Rosa Therapeutics Inc (GLUE) stock in a research note released on January 03, 2023 offered a Overweight rating with a price target of $18. UBS was of a view on October 13, 2022 that the stock is Buy, while Jefferies gave the stock Buy rating on August 15, 2022, issuing a price target of $20. Credit Suisse on their part issued Neutral rating on April 28, 2022.
